74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
D DBV Technologies SA
D
Closed
1.244 9.51
Overview
Share price change
24h
Min
1
Max
1.252
Income | 2.7M -30M |
|---|---|
EPS | -0.288 |
Profit margin | -2,852.369 |
EBITDA | 5.1M -29M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +421.74% upside |
Next Earnings | 10 Apr 2025 |
|---|
Market Cap | 118M |
|---|---|
Previous open | -8.27 |
Previous close | 1.244 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
DBV Technologies SA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
DBV Technologies SA Forecast
Price Target
By TipRanks
421.74% upside
12 Months Forecast
Average 6 EUR 421.74%
High 6 EUR
Low 6 EUR
Based on 1 Wall Street analysts offering 12 month price targets forDBV Technologies SA - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About DBV Technologies SA
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
